Founded in 2021 and headquartered in Pennsylvania, United Research Laboratories (United) is focused on advancing underserved medical conditions in cardiovascular, oncology, and rare diseases. Our partnerships with industry and academia enable new product discovery and development to bring meaningful, differentiated medicines to patients. The United team is comprised of seasoned scientists and business leaders with expertise in advancing assets through regulatory approval and commercialization. Our focus is on your health, developing solutions that matter to those in need, creating opportunities for better health and longer life, and providing greater patient access to those medicines. United is strategically focused on the development of patent-protected, novel products, including a cardiovascular fixed-dose combination therapeutic entering Phase 2 clinical studies. New entities are under evaluation in cardiovascular, oncology and rare diseases, while United continually serves patients with 3 commercial generic products focused on hypertension, anxiety, and alcohol withdrawal syndrome. Additional generic products are under development to provide expanded access to patients who need them in the United States and other regions. As part of our business model, United Research Laboratories establishes drug discovery & development partnerships and license arrangements with companies and institutions holding intellectual property positions on new molecular entities that require technical input, regulatory support, and investment.  We are providing several important elements to the business arrangements that we form by implementing our expertise in drug development from IND enabling through clinical research, by balancing risk and reward for our partners to ensure a collaborative and rewarding strategy and structure, and by offering vetted opportunities to our investors that reduce the risks of bringing new products to patients.